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AbstrAct
Introduction To assess the effect of exenatide and 
pioglitazone or basal- bolus insulin on diabetic peripheral 
neuropathy (DPN) in patients with poorly controlled type 2 
diabetes (T2D).
Research design and methods This is a substudy of 
the Qatar Study, an open- label, randomized controlled 
trial. 38 subjects with poorly controlled T2D were 
studied at baseline and 1- year follow- up and 18 control 
subjects were assessed at baseline only. A combination 
of exenatide (2 mg/week) and pioglitazone (30 mg/day) or 
glargine with aspart insulin were randomly assigned to 
patients to achieve an HbA1c <53 mmol/mol (<7%). DPN 
was assessed with corneal confocal microscopy (CCM), 
DN4, vibration perception and sudomotor function.
Results Subjects with T2D had reduced corneal nerves, 
but other DPN measures were comparable with the control 
group. In the combination treatment arm (n=21), HbA1c 
decreased by 35.2 mmol/mol (3.8 %) (p<0.0001), body 
weight increased by 5.6 kg (p<0.0001), corneal nerve 
branch density increased (p<0.05), vibration perception 
worsened (p<0.05), and DN4 and sudomotor function 
showed no change. In the insulin treatment arm, HbA1c 
decreased by 28.7 mmol/mol (2.7 %) (p<0.0001), body 
weight increased by 4.6 kg (p<0.01), corneal nerve branch 
density and fiber length increased (p≤0.01), vibration 
perception improved (p<0.01), and DN4 and sudomotor 
function showed no change. There was no association 
between the change in CCM measures with change in 
HbA1c, weight or lipids.
Conclusions Treatment with exenatide and pioglitazone or 
basal- bolus insulin results in corneal nerve regeneration, 
but no change in neuropathic symptoms or sudomotor 
function over 1 year.
InTRoduCTIon
Diabetic peripheral neuropathy (DPN) 
affects 50% of patients with diabetes leading 
to neuropathic pain, erectile dysfunction 
and foot ulcers, and imposes a significant 
health and economic burden to both the 
patient and healthcare providers.1 While 
intensive glycemic control can prevent the 
onset or delay progression of DPN in type 1 
diabetes (T1D),2 there are conflicting data 
in type 2 diabetes (T2D).3–9 Both glucagon- 
like peptide 1 (GLP-1) receptor agonists10 11 
and thiazolidinediones (TZDs)5 12–14 produce 
a durable reduction in HbA1c.15 GLP-1 
receptor agonists stimulate insulin secretion 
in response to hyperglycemia, delay gastric 
emptying leading to weight loss and inhibit 
hepatic glucose secretion, while TZDs are 
potent insulin sensitizers and improve β-cell 
function. In preclinical studies, exendin-4, a 
GLP-1 receptor agonist, prevented sensory10 
and motor nerve conduction slowing11 and 
a reduction in intraepidermal nerve fiber 
density (IENFD) in T1D mice. However, twice- 
daily exenatide showed no effect on DPN 
significance of this study
What is already known about this subject?
 ► Improved glycemic control delays the progression of 
diabetic neuropathy in patients with type 1 diabetes 
but has a limited impact in type 2 diabetes.
 ► Glucagon- like peptide 1 receptor agonists, thiazoli-
dinediones and insulin have a neuroprotective effect 
independent of their glucose- lowering effect.
What are the new findings?
 ► Treatment with exenatide and pioglitazone or basal 
bolus insulin was associated with corneal nerve re-
generation, but no change in sudomotor function or 
neuropathic pain.
How might these results change the focus of 
research or clinical practice?
 ► This study provides support for the role of corneal 
confocal microscopy as an endpoint in clinical trials 
of therapies for diabetic neuropathy.
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in patients with T2D.16 TZDs prevent nerve conduction 
slowing,12 maintain myelinated fiber density and reduce 
macrophage infiltration in the sciatic nerve.13 TZDs have 
been shown to reduce the incidence of DPN in patients 
with T2D.5
There are currently no FDA- approved therapies for 
DPN, despite multiple clinical trials. It has been suggested 
that the endpoints in these trials may not be sufficiently 
sensitive to detect a change in DPN.17 Several studies have 
provided support for the prevailing hypothesis that early 
subclinical small fiber injury precedes large fiber damage 
in DPN.18 19 In this study, corneal confocal microscopy 
(CCM) was used to assess early small nerve fiber repair. 
Several longitudinal studies have shown that a lower 
corneal nerve fiber length (CNFL) at baseline predicts 
those patients who develop DPN.20–22 CCM has also been 
used to identify early small fiber repair in several small 
clinical trials.23 24 Indeed, CCM identified early corneal 
nerve regeneration 6 months after pancreas and kidney 
transplantation which was followed by an improvement 
in neuropathic symptoms and nerve conduction after 24 
months.25 26
The Qatar Study15 is an open- label, randomized 
controlled trial, which showed a rapid and effective 
reduction in HbA1c after treatment with a combination 
of exenatide and pioglitazone or basal- bolus insulin in 
patients with poorly controlled T2D. This is a substudy of 
the Qatar Study designed to assess the effect of the two 
treatment arms on DPN with CCM as a primary outcome 
measure and DN4, vibration perception threshold (VPT) 
and sudomotor function as secondary outcome measures. 
This study also evaluated the effect of the treatments on 
diabetic retinopathy.
MaTeRIals and MeTHods
This is a prospective substudy of the Qatar Study,15 an 
open- label, randomized controlled trial ( ClinicalTrials. 
gov identifier NCT02887625) designed to examine the 
efficacy of exenatide plus pioglitazone versus basal- 
bolus insulin in patients with poorly controlled T2D on 
metformin plus sulfonylurea. This substudy was not regis-
tered in a publicly available clinical trial database as it was 
part of the larger Qatar Study. Subjects with T2D were 
enrolled from the National Diabetes Center in Hamad 
General Hospital and studied at baseline and 1- year 
follow- up, and control subjects without diabetes were 
enrolled from Rumailah Hospital and studied between 
October 2016 and November 2018.
study cohort
Subjects were eligible to participate if they were between 
18 and 75 years old, had poorly controlled (HbA1c 
>58 mmol/mol (7.5%)) T2D treated with a maximal dose 
of metformin (>1500 mg/day) plus sulfonylurea (>4 mg 
glimepiride or >60 mg gliclazide), had normal kidney 
and liver function and ECG, and stable body weight 
(±1 kg within the preceding year). Healthy controls had 
a HbA1c <6%.
Exclusion criteria were any cause of neuropathy other 
than diabetes (chemotherapy, HIV infection and hepa-
titis C), factors that may affect the corneal nerves (severe 
dry eyes, severe corneal dystrophies, ocular trauma or 
surgery in the preceding 6 months), a hematocrit <34%, 
medications known to affect glucose metabolism other 
than sulfonylureas and metformin, evidence of diabetic 
proliferative retinopathy, albumin excretion >300 mg/
day and major organ system disease, as determined by 
physical examination, medical history and screening 
blood tests.
Interventions
In the Qatar Study, eligible subjects were randomized 
to receive exenatide plus pioglitazone or glargine and 
aspart to achieve and maintain an HbA1c <53 mmol/mol 
(<7%). There was no limit on the upper value of HbA1c 
for enrollment. Subjects randomized to combination 
treatment were started on weekly subcutaneous extended 
release exenatide (2 mg/week Bydureon) and pioglita-
zone (30 mg/day). Subjects receiving insulin were started 
on glargine before breakfast. The Treat- to- Target Trial 
(4T) algorithm was used to calculate the starting glargine 
dose, and the dose was adjusted weekly to achieve a 
fasting plasma glucose (FPG) of <6.11 mmol/L. After 
the FPG goal was achieved, if the HbA1c was >53 mmol/
mol (>7.0%), 4–6 U of insulin aspart was started before 
each meal, and the dose was adjusted to achieve a post- 
prandial plasma glucose concentration of <7.78 mmol/L, 
2 hours after meals. Patients were seen monthly during 
the first 4 months or as needed, based on the results of the 
plasma glucose concentration, and bimonthly thereafter. 
The percentage of subjects experiencing hypoglycemia 
during the 1- year trial was calculated as the number of 
subjects experiencing at least one single episode of hypo-
glycemia (blood glucose concentration <60 mg/dL with 
or without symptoms or hypoglycemic symptoms that 
subsided following glucose ingestion) divided by the 
number of patients in that arm as per the protocol in the 
Qatar Study.15
diabetic neuropathy assessment
CCM was performed using a Heidelberg Retina Tomo-
graph 3 with the Rostock Cornea Module (Heidelberg 
Engineering GmbH). The CCM uses a 670 nm diode 
laser and provides digital images of the cornea. The 
technique has been previously described.27 Briefly, both 
eyes were anesthetized using oxybuprocaine hydrochlo-
ride 0.4% (Conjuncain EDO; Fabrik GmbH) followed 
by a drop of carbomer 0.2% eye gel (Blumont Health-
care), and patients were instructed to fixate on a target. 
Several scans of the sub- basal nerve plexus in the central 
cornea were captured per eye for 2 min. Adjacent images 
were separated by approximately 1–4 µm. CCM image 
extraction was carried out at a separate time by one investi-
gator unaware of the treatment group. Three high- clarity 
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CCM images per eye were selected based on a previously 
published protocol,27 and images were selected based on 
depth, focus position and contrast.28 Corneal nerve fiber 
density (CNFD) (fibers/mm2), corneal nerve branch 
density (CNBD) (branches/mm2) and corneal nerve 
fiber length (CNFL) (mm/mm2) were quantified using 
CCMetrics, a validated image analysis software.29
Vibration perception threshold (VPT) was measured 
using a Neurothesiometer (Horwell Scientific Laboratory 
Supplies) on the pulp of the large toe on both feet and 
the average value of three measurements was recorded as 
a VPT in volts (V) ranging from 0 to 50 V.
Sudomotor function was measured by electrochem-
ical skin conductance (ESC) using Sudoscan (Impeto 
Medical SAS) as described previously. Sudoscan evaluates 
sympathetic innervation based on sweat chloride concen-
trations generated by the sweat gland in response to the 
voltage applied and is reported as ESC in microSiemens 
(µS).
Neuropathic pain was assessed using the Douleur 
Neuropathique en 4 (DN4) questionnaire as previously 
described.26
diabetic retinopathy assessment
Ophthalmic examination was carried using a non- contact 
slit- lamp biomicroscope (Topcon) with +90 D lens (Volk) 
and two digital retinal images of both eyes were taken 
using a digital fundus camera (Zeiss) after pupil dilata-
tion with Tropicamide 1% in 16/21 patients in the combi-
nation treatment group and 9/17 patients in the insulin 
treatment group. Diabetic retinopathy was graded by two 
qualified investigators according to the NHS Diabetic 
Eye Screening Programme.30 Diabetic retinopathy was 
graded as R0 for no diabetic retinopathy; R1 for the pres-
ence of microaneurysms, retinal hemorrhages, venous 
loops, exudates or cotton wool spots in the presence of 
other features of diabetic retinopathy; and R2 for the 
presence of venous beading, reduplication, multiple 
blot hemorrhages or intraretinal microvascular abnor-
mality. Diabetic proliferative retinopathy (R3) was an 
exclusion criterion. Maculopathy was defined as M0 for 
no maculopathy or for any microaneurysm or hemor-
rhage within 1 disc diameter of the center of the fovea 
if associated with a best visual acuity of 6/12 where the 
cause of the reduced vision is known and is not diabetic 
macular edema and M1 for exudate, retinal thickening, 
microaneurysm or hemorrhage within 1 disc diameter of 
the center of the fovea or a group of exudates within the 
macula.
outcome measures
The primary outcome measures were the CCM measures 
and the secondary outcome measures were DN4, VPT 
and sudomotor function.
statistical analysis
This substudy was not adjusted for multiple compari-
sons.31 The results were analyzed as an exploratory study. 
Continuous variables between controls, subjects with 
T2D treated with exenatide plus pioglitazone and insulin 
were compared using one- way ANOVA. Continuous vari-
ables between the two groups were compared using an 
unpaired t- test. Categorical variables were compared 
using χ2. Changes between baseline and 1- year follow- up 
were compared using a paired t- test. Correlation of the 
change in CCM measures with the change in HbA1c, 
body weight and lipids were analyzed using the Pearson 
correlation coefficient. All analyses were performed 




The exenatide plus pioglitazone (n=21) and insulin (n=17) 
group had comparable HbA1c (92.5±18.8 mmol/mol 
(10.6%±1.7%) vs 89.9±22.5 mmol/mol (10.4%±2.1%), 
p=0.7) and significantly higher than the control group 
(41.6±5.0 mmol/mol (6.0%±0.5%), p<0.0001) (table 1). 
The mean age, gender, lipid profile, diastolic blood 
pressure, body weight and body mass index (BMI) were 
comparable between all three groups. The systolic blood 
pressure in the combination treatment group was signifi-
cantly lower than in the control group (126.4 mm Hg vs 
143.7 mm Hg, p<0.05). The percentage of patients with 
diabetic retinopathy was comparable between the two 
treatment groups (31.3% vs 44.4%, p=0.51).
The combination treatment group had significantly 
lower CNFD (fibers/mm2) (26.1 vs 33.7, p=0.01), CNBD 
(branches/mm2) (57.0 vs 110.4, p<0.001) and CNFL 
(mm/mm2) (17.8 vs 25.1, p=0.0001) compared with 
the control group. The insulin treatment group had 
significantly lower CNBD (70.3 branches/mm2, p<0.01) 
and CNFL (19.4 mm/mm2, p<0.01) compared with the 
control group. There was no difference in vibration 
perception threshold and sudomotor function measured 
by electrochemical skin conductance between the three 
groups and the percentage of patients with neuropathic 
pain (DN4 >4) was comparable between the treatment 
groups.
Change in clinical and metabolic variables
HbA1c reduced significantly in both treatment groups 
(p<0.0001), more so with exenatide plus pioglitazone 
compared with basal- bolus insulin (35.2 mmol/mol 
(3.8%) vs 28.7 mmol/mol (2.7%), p<0.05) (figure 1). 
The mean HbA1c at 1- year follow- up was lower but 
not significant in the combination treatment group 
(51.4±12.0 mmol/mol (6.9%±1.1%) vs 60.2±18.2 mmol/
mol (7.7%±1.7%), p=0.1) (table 2). A higher percentage 
of patients achieved the American Diabetes Association 
treatment goal of HbA1c <53 mmol/mol (<7.0%) in the 
combination treatment group compared with the insulin 
treatment group (15/21 (71.4%) vs 6/17 (35.3%), 
p<0.05). The percentage of patients with hypoglycemia 
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Table 1 Baseline characteristics of patients with type 2 diabetes who received exenatide plus pioglitazone or insulin 
treatment
Controls (n=18) Exenatide plus pioglitazone (n=21) Basal- bolus insulin (n=17) P value
Age, years 53.0±11.0 50.1 ±9.4 54.9 ±7.5 0.30
Male, n (%) 13/18 (72.2) 11/21 (52.4) 12/17 (70.6) 0.35
Duration of diabetes, years NA 10.0 ±5.9 13.1 ±9.3 0.24
HbA1c, mmol/mol 41.6±5.0 92.5 ±18.8**** 89.9 ±22.5**** <0.0001
HbA1c, % 6.0±0.5 10.6 ±1.7**** 10.4 ±2.1****
Total cholesterol, mmol/L 5.0±1.0 4.7 ±0.6 5.3 ±1.3 0.17
Triglyceride, mmol/L 1.4±0.5 2.0 ±1.4 1.8 ±1.0 0.37
HDL, mmol/L 1.2±0.3 1.3 ±0.6 1.2 ±0.4 0.87
LDL, mmol/L 3.2±0.9 2.6 ±0.7 3.1 ±1.0 0.10
Systolic BP, mm Hg 143.7±12.7 126.4 ±17.9* 130.8 ±19.3 0.02
Diastolic BP, mm Hg 82.1±6.6 78.2 ±13.9 77.6 ±10.4 0.50
Body weight, kg 75.8±4.7 87.9 ±19.5 84.3 ±13.7 0.07
BMI, kg/m2 28.8±3.4 32.4 ±6.7 30.4 ±5.9 0.2
Diabetic retinopathy, n (%)   5/16 (31.3) 4/9 (44.4) 0.51
Neuropathic pain, n (%)   4/18 (22.2) 2/12 (16.7) 0.71
CNFD, fibers/mm2 33.7±5.7 26.1 ±7.9** 28.8 ±9.1 0.01
CNBD, branches/mm2 110.4±45.0 57.0 ±31.6*** 70.3 ±31.2** <0.001
CNFL, mm/mm2 25.1±4.3 17.8 ±4.9**** 19.4 ±5.7** 0.0001
VPT, V 7.2±4.1 7.3 ±4.6 11.4 ±7.4 0.08
ESC feet, µS 66.9±18.4 59.8 ±25.7 67.2 ±12.0 0.55
Numeric variables and frequency distribution for categorical variables are summarized as means±SD or n (%). Variables were compared 
using one- way ANOVA except for duration of diabetes which was compared using unpaired t- test. Categorical variables were compared 
using χ2. Variables that were significantly different between controls and patients with T2D were denoted as *p≤0.05, **p≤0.01, ***p≤0.001, 
****p≤0.0001.
BMI, body mass index; BP, blood pressure; CNBD, corneal nerve branch density; CNFD, corneal nerve fiber density; CNFL, corneal nerve 
fiber length; ESC, electrochemical skin conductance; HDL, high- density lipoprotein cholesterol; LDL, low- density lipoprotein cholesterol; NA, 
not available; T2D, type 2 diabetes; VPT, vibration perception threshold.
Figure 1 Effect of exenatide plus pioglitazone and insulin 
treatment on HbA1c over 1 year. Overall HbA1c changes 
between different time points were compared using paired 
t- test: ‡p≤0.05, †p≤0.01, ††p≤0.001, †††p≤0.0001.
in the insulin group was significantly higher than the 
combination group (84.6% vs 38.1%, p=0.008).
Body weight increased by 4.6 kg in the insulin group 
and by 5.6 kg in the combination treatment group 
(p<0.01) (figure 2).
In both treatment groups, total cholesterol decreased 
by 0.5–0.8 mmol/L (p<0.05–0.001). In the combination 
treatment group, triglycerides decreased by 0.4 mmol/L 
(p<0.05) and diastolic blood pressure decreased by 
8.9 mm Hg (p<0.0001) and high- density lipoprotein 
cholesterol (HDL) increased by 0.4 mmol/L (p<0.01).
Change in neuropathy measures
In the insulin treatment group, CNBD and CNFL 
increased by 27.2 branches/mm2 (p=0.01) and 2.3 mm/
mm2 (p<0.01), respectively, with no change in CNFD 
(figures 2 and 3). In the exenatide plus pioglitazone 
treatment group, CNBD increased by 19.0 branches/
mm2 (p=0.02) with no change in CNFD (p=0.76) and 
CNFL (p=0.12). Between the treatment groups, the 
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Table 2 Changes in clinical and metabolic variables and measures of DPN after 1 year of exenatide plus pioglitazone or 
insulin treatment
Exenatide plus pioglitazone (n=21) Basal- bolus insulin (n=17)
P value1 P value21- year follow- up Change 1- year follow- up Change
HbA1c, mmol/mol 51.4 ±12.0 −35.2**** 60.2 ±18.2 −28.7**** 0.1 <0.05
Hb1Ac, % 6.9 ±1.1 −3.8**** 7.7 ±1.7 −2.7****
Total cholesterol, mmol/L 4.2 ±0.8 −0.5*** 4.5 ±0.9 −0.8* 0.28 0.40
Triglyceride, mmol/L 1.6 ±1.3 −0.4* 1.4 ±0.7 −0.4 0.57 1.00
HDL, mmol/L 1.2 ±0.3 −0.1 1.1 ±0.2 −0.1 0.40 0.82
LDL, mmol/L 2.2 ±0.8 −0.4** 2.7 ±0.8 −0.3 0.06 0.92
Systolic BP, mm Hg 123.4 ±16.8 −3.0 130.4 ±15.8 −0.4 0.20 0.65
Diastolic BP, mm Hg 69.3 ±10.5 −8.9**** 73.9 ±10.6 −3.8 0.20 0.14
Body weight, kg 93.5 ±22.0 5.6**** 88.9 ±15.8 4.6** 0.47 0.62
BMI, kg/m2 33.2 ±7.3 0.8* 30.1 ±5.5 −0.3 0.17 0.09
Diabetic retinopathy, n (%) 13/16 (81.3) 8** 6/9 (66.7) 2 0.41
Neuropathic pain, n (%) 2/18 (11.1) −2 2/12 (16.7) 0 0.66
CNFD, fibers/mm2 26.6 ±5.3 0.6 30.8 ±8.9 2.0 0.11 0.61
CNBD, branches/mm2 76.0 ±38.6 19.0* 97.4 ±54.2 27.2** 0.20 0.51
CNFL, mm/mm2 19.7 ±4.8 1.9 21.7 ±5.8 2.3** 0.28 0.79
VPT, V 9.0 ±5.4 1.7* 8.7 ±5.9 −2.8** 0.87 0.001
ESC feet, µS 61.8 ±23.4 2.0 65.5 ±15.3 −1.7 0.65 0.53
P value1 for combination vs insulin therapy at 1- year follow- up.
P value2 for combination vs insulin therapy changes at 1- year follow- up.
Numeric variables and frequency distribution for categorical variables are summarized as means±SD or n (%). Continuous variable between 
exenatide plus pioglitazone and insulin treatment were compared using unpaired t- test. Categorical variables were compared using χ2. 
Changes between baseline and 1- year follow- up were compared using paired t- test: *p≤0.05, **p≤0.01, ***p≤0.001, ****p≤0.0001.
BMI, body mass index; BP, blood pressure; CNBD, corneal nerve branch density; CNFD, corneal nerve fiber density; CNFL, corneal nerve 
fiber length; DPN, diabetic peripheral neuropathy; ESC, electrochemical skin conductance; HDL, high- density lipoprotein cholesterol; LDL, 
low- density lipoprotein cholesterol; VPT, vibration perception threshold.
change in CNFD (26.6 fibers/mm2 vs 30.8 fibers/mm2, 
p=0.11), CNBD (76.0 branches/mm2 vs 97.4 branches/
mm2, p=0.20) and CNFL (19.7 mm/mm2 vs 21.7 mm/
mm2, p=0.28) were comparable.
Vibration perception threshold decreased by 2.8 V 
(p<0.01) in the insulin treatment group and increased by 
1.7 V (p<0.05) in the combination treatment group, with 
a significant difference between the two treatment groups 
at 1- year follow- up (p=0.001) (table 2 and figure 2).
There was no significant change in the percentage of 
patients with neuropathic pain (DN4 >4). There was no 
change in sudomotor function in either treatment group 
(table 2).
Correlation between change in CCM measures with change in 
Hb1ac, lipids and weight
There was no correlation between the percentage 
change in CNFD with percentage change in HbA1c 
(r=0.06, p=0.74), total cholesterol (r=0.16, p=0.37), 
triglycerides (r=0.20, p=0.25), HDL (r=0.08, p=0.66) 
and weight (r=0.24, p=0.17). There was no correlation 
between percentage change in CNBD with percentage 
change in HbA1c (r=0.01, p=0.95), total cholesterol 
(r=0.06, p=0.74), triglycerides (r=0.08, p=0.64), HDL 
(r=0.06, p=0.73) and weight (r=0.25, p=0.14). There was 
no correlation between percentage change in CNFL 
with percentage change in HbA1c (r=0.05, p=0.77), 
total cholesterol (r=0.12, p=0.49), triglycerides (r=0.14, 
p=0.42), HDL (r=0.04, p=0.82) and weight (r=0.03, 
p=0.84).
diabetic retinopathy
The percentage of patients with new- onset diabetic reti-
nopathy increased significantly from 31.3% to 81.3% 
(p<0.01) in the combination treatment group and while 
there was an increase in the insulin treatment group 
from 44.4% to 66.7%, this was not significant (table 2). 
Eight subjects in the combination treatment group and 
two subjects in the insulin group progressed from R0 to 
R1. There was no progression of retinopathy in subjects 
graded R1, R2, M0 or M1 at baseline.
dIsCussIon
This study shows that combination treatment with exen-
atide plus pioglitazone or basal- bolus insulin over 12 
months results in a marked improvement in HbA1c, 
but with weight gain, and hypoglycemia, consistent 
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Figure 2 Effect of exenatide plus pioglitazone and insulin treatment on HbA1c, lipid profile, blood pressure, body weight, 
corneal nerve fiber measures, vibration perception threshold and sudomotor function in the feet over 1- year follow- up. DBP, 
diastolic blood pressure; ESC, electrochemical skin conductance; HDL, high- density lipoprotein cholesterol; LDL, low- density 
lipoprotein cholesterol; SBP, systolic blood pressure; VPT, vibration perception threshold.
with the Qatar Study.15 Insulin treatment was associated 
with a significant improvement in distal corneal nerve 
morphology characterized by an increase in corneal 
nerve branch density and length and an improvement 
in vibration perception, but no change in sudomotor 
function or incidence of neuropathic pain. Combina-
tion treatment was associated with an improvement in 
the lipid profile, blood pressure and an increase in distal 
corneal nerve branch density, but a small but significant 
deterioration in VPT with no change in sudomotor func-
tion or incidence of neuropathic pain. The improve-
ment in CCM measures were independent of changes in 
HbA1c, body weight and lipids. There was an increase in 
the incidence of diabetic retinopathy in the combination 
treatment group.
While exenatide results in weight loss,16 pioglitazone 
is associated with weight gain, explaining the increase in 
weight observed in the combination treatment group. 
Obesity32 is a risk factor for DPN. Jaiswal et al16 reported 
that exenatide resulted in 3 kg weight loss after 1 year, 
compared with 2 kg weight gain with glargine.4 6 Pioglita-
zone is associated with a lowering of diastolic blood pres-
sure and triglycerides, and we also observed a significant 
reduction in diastolic blood pressure and triglycerides in 
the combination treatment group. Hypertension33 and 
hyperlipidemia34 are also risk factors for DPN. However, 
the weight gain in both treatment arms may have limited 
the overall benefit on neuropathy.
Glucagon- like peptide 1 (GLP-1) receptor agonists 
have been reported to have a neuroprotective effect. In 
preclinical studies, Himeno et al11 showed that exendin-4 
prevented both sensory and motor nerve conduction 
slowing and reduction of IENFD. However, Kan et al10 
reported that exendin-4 prevented sensory nerve conduc-
tion slowing but had no effect on motor nerve conduc-
tion slowing and epidermal innervation. Conversely, in 
T2D mice, exendin-4 prevented motor nerve conduc-
tion slowing but had no effect on sensory nerve conduc-
tion. In a clinical trial of patients with T2D treated with 
exenatide, there was no effect on the incidence of DPN, 
cardiovascular autonomic neuropathy (CAN) or IENFD 
over 18 months.16 Recently, the LEADER trial35 showed 
that liraglutide was associated with a significantly lower 
risk of amputations related to diabetic foot ulceration in 
patients with T2D. However, a study of 39 patients with 
T1D and established neuropathy randomized to liraglu-
tide or placebo over 26 weeks recently failed to show a 
benefit on autonomic function or sensory and motor 
nerve conduction.36 TZDs have also been reported to 
have a neuroprotective effect. In preclinical studies, 
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Figure 3 Corneal confocal microscopy images of the sub- basal nerve plexus. Corneal nerve morphology in healthy age- 
matched controls (A), people with type 2 diabetes treated with exenatide and pioglitazone (B, C) and basal- bolus insulin (D, 
E) at baseline and 1- year follow- up. The red arrows indicate the fibers that might have increased the measurement of nerve 
branches and fiber length in the insulin treatment group at 1- year follow- up.
Qiang et al12 reported that troglitazone prevented nerve 
conduction slowing and maintained normal myelinated 
fiber architecture and density in T1D rats. Yamagishi 
et al13 confirmed that pioglitazone prevented nerve 
conduction slowing and reduced macrophage infiltra-
tion in the sciatic nerve in T1D rats. Wiggin et al14 showed 
that rosiglitazone prevented thermal hypoalgesia and 
reduced oxidative stress in the sciatic nerve of T1D mice. 
In the BARI 2D trial,5 rosiglitazone significantly reduced 
the 4- year cumulative incidence of DPN compared with 
insulin treatment. The neuroprotective effect of TZDs 
may be attributed to a reduction in oxidative stress and 
advanced glycated end products. Our data suggest that 
exenatide plus pioglitazone treatment may be associated 
with small fiber regeneration, assessed using CCM.
In preclinical studies, Kan et al10 reported that high- 
dose insulin prevented a reduction of IENFD in T1D 
mice but had no effect in T2D mice. In the DCCT, inten-
sive insulin treatment reduced the incidence of clinical 
DPN by 60%2 and prevented peroneal nerve conduc-
tion velocity slowing over a 5- year period in patients with 
T1D. However, in patients with T2D, the UKPDS6 and 
VA- CSDM trial7 reported that intensive treatment had no 
effect on the incidence of DPN and CAN compared with 
conventional treatment. The Kumamoto study3 showed 
that intensive treatment prevented nerve conduction 
slowing over 6 years and the ACCORD trial4 showed a 
reduction in the incidence of loss of ankle reflexes but 
no effect on VPT over 6 years.8 Our data suggest that 
insulin treatment might have a beneficial effect on DPN, 
independent of the improvement in glycemic control as 
there was evidence of greater small nerve fiber regener-
ation and an improvement in vibration perception. In 
a previous study comparing continuous subcutaneous 
insulin infusion (CSII) with multiple daily insulin injec-
tion, we showed that despite a comparable HbA1c, the 
CSII group showed an increase in CNFD, CNBD and 
CNFL,37 which was attributed to a direct neurotrophic 
effect of insulin.38
Both combination and insulin treatment improved 
corneal nerve fiber measures but had no effect on neuro-
pathic symptoms or sudomotor function over 1 year. This 
is consistent with studies showing corneal nerve regener-
ation 6 months after pancreas and kidney transplantation 
in T1D with no change in quantitative sensory testing and 
an improvement in neuropathic symptoms and nerve 
conduction at 24 and 36 months.25 26 39 Autonomic func-
tion has not been shown to improve 3, 8 and 10 years after 
kidney and pancreas transplantation,26 40 41 but multifac-
torial risk factor reduction showed an improvement in 
cardiac autonomic function with no change in vibra-
tion perception threshold.42 A recent study from Japan 
showed that multifactorial risk factor reduction achieved 
by improving and even normalizing glycemic control and 
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reducing body weight and blood pressure in patients with 
T2D over 4 years resulted in an improvement in CNFL, 
CNBD, neurophysiology and vibration perception, which 
correlated with the reduction in HbA1c.43 The present 
study shows an improvement in CNBD and CNFL, but no 
change in sudomotor function over 12 months. Jaiswal 
et al16 reported a trend for a greater increase in IENFD 
1 year after capsaicin denervation in patients on insulin 
compared with exenatide. In a randomized placebo- 
controlled trial of once- weekly C- peptide, there was no 
improvement in sural nerve conduction velocity or the 
modified Toronto Clinical Neuropathy Score and yet 
vibration perception threshold improved significantly.44 
These findings emphasize the importance of the type 
and duration of intervention and choice of endpoints in 
clinical trials of DPN.
A large improvement in HbA1c (>2%–3%) has been 
reported to be associated with treatment- induced neuro-
pathic pain, autonomic neuropathy, and a worsening 
of retinopathy and microalbuminuria.45 Our study 
shows that despite a reduction in HbA1c of 3.8% with 
a combination of exenatide and pioglitazone and 2.7% 
with insulin, there was no increase in the incidence of 
painful DPN. However, the genesis of painful neurop-
athy is complex and may involve alterations in transient 
receptor potential channels, which may not have been 
altered by the current interventions.46 The incidence of 
diabetic retinopathy increased, especially in the combina-
tion treatment group. GLP-1 therapy has been associated 
with an increase in the risk of retinopathy progression in 
patients with diabetic retinopathy in a large randomized 
trial with semaglutide,47 although two large population- 
based analyses have failed to confirm this association.48 49 
Treatment with lixisenatide and once- weekly exenatide 
have previously shown no adverse effect on retinopathy.49
We acknowledge that this is a small open- label study 
with a lack of blinding for participants and investigators 
due to weekly exenatide injections and multiple daily 
insulin injections. However, the investigator that evalu-
ated the neuropathy outcome measures was masked to 
the treatment group. Our cohort of patients with T2D 
had minimal neuropathy and a very effective reduction 
in HbA1c over 12 months leading to early small nerve 
fiber repair as observed after simultaneous pancreas–
kidney transplantation26 or optimal medical therapy.43
In conclusion, exenatide plus pioglitazone or basal- 
bolus insulin treatment effectively reduces HbA1c and 
promotes small fiber regeneration. While the incidence 
of diabetic retinopathy increased, especially in the combi-
nation treatment group, there was no impact on neuro-
pathic pain. Our findings support the utility of CCM as 
an early surrogate marker of therapeutic response in clin-
ical trials of diabetic neuropathy.
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